GlassScriptPhysician profile
Tara L Braun
NPI 1407353303
$6,955.44
in general payments reported to CMS, 2019-2025
28 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.79 · 2022: $740 · 2023: $1,702 · 2024: $3,130 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,841 · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,840.97 |
| Education | $361.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,040.95 | 2022-2025 | Rinvoq, Skyrizi, Botox |
| Janssen Biotech, INC. | $769.55 | 2023-2025 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $736.46 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $514.25 | 2022-2025 | Sotyktu |
| Incyte Corporation | $498.95 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $468.02 | 2022-2025 | Adbry |
| Lilly USA, LLC | $391.42 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $366.45 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $359.00 | 2022-2025 | Libtayo, Dupixent |
| Amgen INC. | $289.67 | 2023-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $284.69 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $283.68 | 2022-2025 | Absorica Ld, Winlevi |
| Pfizer INC. | $214.19 | 2023-2025 | |
| Dermavant Sciences, INC. | $133.69 | 2023-2024 | Vtama |
| Ucb, INC. | $130.98 | 2024-2025 | Bimzelx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $119.28 | 2021-2025 | Nemluvio, Twyneo, Oracea |
| Mayne Pharma Commercial LLC | $70.20 | 2023 | |
| Strata Skin Sciences, INC. | $61.81 | 2023-2024 | Xtrac |
| Merz North America, INC. | $38.74 | 2024-2025 | |
| Organon LLC | $36.16 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.92 | 2025 | Spevigo |
| Genentech USA, INC. | $20.45 | 2024 | Erivedge |
| Paratek Pharmaceuticals, INC. | $18.94 | 2024 | Nuzyra |
| Tempus Ai, INC | $18.34 | 2024 | Merlin Test |
| Cipher Pharmaceuticals US LLC | $18.14 | 2025 | Natroba, Spinosad |
| Verrica Pharmaceuticals INC. | $15.55 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.13 | 2023 | Jublia |
| Solta Medical, A Division of Bausch Health US, LLC | $14.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Braun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.